肿瘤微血管密度与肝癌病理及预后关系

目的 探讨肿瘤微血管密度（MVD）与肝细胞性肝癌临床病理及预后的关系。方法对30例肝细胞性肝癌根治性切除病理组织切片进行苏木精伊红染色．并用CD34单克隆抗体进行免疫组化染色，计数被CD34抗体染色的肿瘤血管内皮细胞数，以测定MVD。对MVD与临床病理因素及术后生存率关系进行分析。结果 单因素分析结果表明．MVD水平与肿瘤大小、TNM分期都是影响肝细胞性肝癌预后的因素；多因素分析结果表明．肝癌大小及肿瘤分期是肝细胞性肝癌独立预后因素。结论 MVD是肝细胞性肝癌一种预后因素。     

多脏器功能不全综合征患者并发肠源性感染的胃肠功能保护

目的 探讨多脏器功能不全综合征(MODS)患者肠源性感染时胃肠功能管理及预后。方法对32例MODS中伴胃肠衰竭的13例患者的临床资料进行分析。结果 32例MODS患者中，伴发胃肠功能衰竭者13例，ll例成活，2例死亡，死亡率15、4％。结论 重视胃肠功能管理，加强胃肠功能保护是提高MODS患者救治率的重要因素。     

CT影像学评分预测急性胰腺炎病情及转归的研究

目的 探讨CT影像学评分对急性胰腺炎病情和转归的预测价值。方法 回顾性分析入院后经CT检查的急性胰腺炎46例，按一定的规则对每例患进行CT影像学评分与分型，并与临床治疗中的有关资料进行对照。结果 46例患CT评分后获得：轻型24例，中型13例，重型9例。轻型患较重型住院日少、恢复顺利，中转手术及死亡率均以重型为高。结论 CT评分对急性胰腺炎病情及预后评估具有重要意义。     

32例青年食管癌临床病理分析

目的：探讨青年食管癌患者的临床病理特点。方法：以病例对照方式对32例青年食管癌临床病理特点进行分析，选用同期50岁以上食管癌病例40例为对照组。结果：青年食管癌患者与老年者相比，病理分化程度低，恶性度高，早期诊断率低，生存期短。结论：青年食管癌症状隐匿，诊断率低，预后差。     

Predictors of survival in 171 patients with systemic sclerosis (scleroderma)

Summary Predictors of survival were determined in 171 patients with systemic sclerosis by univariate analysis, and the Cox proportional hazards model using both cross sectional data at entry into the follow-up and time-dependent follow-up data. Clinical and laboratory data were evaluated from 1982 to the end of 1993. The presence of diffuse scleroderma, kidney and cardiac involvements were unfavourable prognostic signs in both the univariate analysis, and the Cox proportional hazards models. The Cox model, using the variables detected at study entry, indicated that pericarditis, and anaemia were bad prognostic signs. Analysis with time dependent data has not been reported in systemic sclerosis. The appearance of pigmentation disturbances, anaemia, and respiratory failure during the follow-up also caused a poor prognosis of the disease by the Cox model. In the stepwise selection models, diffuse scleroderma, internal organ manifestations including renal, and cardiac involvements were predominantly selected as the most unfavourable factors for survival. As to the extent of skin involvement and internal organ manifestations, the general behaviour of the disease seems to be similar throughout the world. The early appearance of pericarditis and pigmentation disturbances at study entry are bad prognostic signs.This work was supported by the Hungarian Ministry of Health and Social Welfare and by the National Foundation for Scientific Research.     

胃癌组织内微血管定量的意义

目的：研究胃癌组织中微血管数量（MVC）与临床病理因素及预后的关系。方法：材料取自瑞金医院1988年～1991年胃癌手术切除标本，共128例。抗因子Ⅷ相关抗原（F-ⅧRAg）的单克隆抗体和免疫组化试剂盒购自Dako公司。研究方法按LSAB法免疫组织化学操作技术常规进行；微血管定量以镜下200倍，肿瘤内5个最高微血管密度区的MVC均数表示；分析MVC与临床病理因素之间关系，并对有完整5年随访资料的86例胃癌患者预后与MVC关系进行探讨。结果：所有胃癌组织中的平均MVC为16.5±8．5，MVC随TNM分期增加而增加，有淋巴结转移患者的MVC（18．3±8.7）明显高于无淋巴结转移患者（13．8±7．4）（P＜0．01），高MVC（≥16）胃癌患者比低MVC（＜16）患者预后明显为差，5年生存率分别为42.5％和58．7％（P＜0．05）。结论：MVC在胃癌患者是一个有意义的预后指标．     

重型颅脑损伤持续颅内压及脑灌注压监护与预后关系

作者对５０例重型颅脑损伤患者（ＧＣＳ３－８分），及５０例伤情与诊断和手术方式基本相似的另一组患者进行颅内压（ＩＣＰ）与脑灌注压（ＣＣＰ）连续监测对比研究。结果表明，监护组除８例ＩＣＰ压力＜２．００ｋＰａ，ＣＰＰ＞９．３３ｋＰａ外，余４２例均有不同程度ＩＣＰ增高与ＣＰＰ降低。这些患者分别为创伤性颅内血肿、广泛性脑挫裂伤、继发性脑水肿或脑肿胀等，均采取积极的手术及综合治疗。死亡率为１４％。非监护组治疗方法与监护组相同，预后较差且并发症多，死亡率为２８％。作者认为，对重型颅脑损伤患者施行连续ＩＣＰ、ＣＰＰ监护，是降低并发症和死亡率，提高疗效的有力措施，具有重要的临床应用价值。     

Role of blast cell immunophenotyping for the diagnosis and prognosis of acute myeloid leukemia.

Bone marrow blast cell antigen expression from 86 patients with de novo acute myeloid leukemias (AML) was studied and correlated with FAB classification and clinical outcome. Among a panel of 14 monoclonal antibodies routinely used for the diagnosis of acute leukemias we studied the expression of six antibodies (CD13, CD15, VIM2, CD33, CD14, CD34) of the granulomonocytic lineage and found that some of them were useful for diagnosis and/or prognosis. For FAB subclassification of AML, the CD13 or VIM2 antigen expression was of no benefit. Monocytic leukemias (M4 + M5PD + M5WD) more frequently expressed CD34 antigen (28/31) than granulocytic (M1 + M2 + M3) subtypes (33/53) (P < 0.01). Finally, the most striking differences were found with CD14 antigen expression: CD14 antigen was more frequently expressed in M4 + M5 leukemias (21/31) than in M1 + M2 + M3 subtypes (12/33) (P < 0.01). The mean percentage of CD14 positive blast cells was accordingly higher in monocytic leukemias than in granulocytic leukemias and the difference was highly significant (P < 0.0001). The CD15 antigen was more frequently expressed in differentiated leukemias (M2 + M3 + M4 + M5WD) (35/44) than in poorly differentiated forms (M1 + M5PD) (17/37) (P < 0.001). The statistical difference was higher when the mean percentage of CD15 positive blast cells were compared (P < 0.0003). Moreover these latter percentages were different in M1 and M2 subtypes (P < 0.003). The blast cell expression of CD13, CD14, CD15 or CD33 was not predictive of the length of CR or survival. Moreover, our results support previously published findings suggesting a longer overall survival duration for patients whose leukemic cells do not express the CD34 antigen (P < 0.01). We also confirm that patients with the more differentiated subtypes of AML (CD13-, CD34+) tend to survive longer than patients with the less differentiated subtypes of AML (CD13-, CD34+) (P < 0.001).     

The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram

Between 10% and 25% of patients with newly diagnosed prostate cancer without bone metastases at the time of diagnosis will develop metastases during follow-up. To determine the value of clinical and biochemical parameters for assessment of prognosis at the time of diagnosis, a retrospective study was performed in 124 consecutive patients with newly diagnosed prostate cancer without bone metastases. The mean follow-up was 41 months, during which time 36 patients died and 15 patients developed metastases. Bone scans were classified from 0 (=normal) through 2 (=abnormal, but not typical for metastases) and were correlated with age, alkaline phosphatase (AP), prostate-specific antigen (PSA), tumour grade, T-stage and N-stage. In patients with a class 2 scan, additional roentgenograms and follow-up were used to exclude metastases at initial stage. All parameters, including therapy, were finally correlated with the development of metastases and survival. For survival 38 patients with proven metastases were used as controls. For all parameters tested, no statistically significant differences were found between the three bone scan classifications. The interval between diagnosis and the development of metastases ranged from 12 to 72 months. For the risk of development of metastases only PSA was found to be a significant correlate (P=0.0075). However, when tumour stages were clustered in limited disease (T0–2) and extensive disease (T3–4), the incidence of metastases was significantly higher in patients with extensive disease than in those with limited disease (P=0.0021). Finally, age, PSA and Anderson classification were found to be significant correlates of survival, but in stepwise analysis PSA was selected as the most prognostic variable (P<0.0001). In contrast with a typical pattern of metastases on bone scintigraphy, an abnormal scan (class 1 and 2) at the time of diagnosis is not a poor prognostic parameter of the risk of death. In conclusion, in patients with prostate cancer without bone metastases at the time of diagnosis, pretreatment PSA and tumour stage can be used for the assessment of risk of development of metastases during follow-up and survival. For this purpose, tumour stage should be clustered in limited and extensive disease. Received 14 April and in revised form 9 June 1997     

中期因子和微血管密度在乳腺癌中的表达

目的　探讨中期因子 (MK)与微血管密度 (MVD)的表达与乳腺癌生物学行为的关系及对预后的意义。方法　采用免疫组织化学方法检测 67例乳腺浸润性导管癌组织MK、MVD表达水平 ,并对其与乳腺癌临床病理特征的关系进行统计学分析。结果　本组 67例中 ,MK阳性表达者 3 7例 ,占 5 5 .2 %。MK表达水平及MVD值均与肿块大小 ,腋淋巴结状态及复发和转移有关。MK表达阳性者的MVD均值 (90 .75± 3 3 .0 5 )明显高于MK表达阴性组 (70 .48± 3 1.3 3 ,P <0 .0 1)。结论　MK在乳腺癌血管生成中发挥重要作用 ,MK的阳性表达与乳腺癌的发生、发展和预后密切相关 ,可作为一种有价值的肿瘤标志和预后指标。